RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Here's a link to the report -


https://www.sec.gov/Archives/edgar/data/849636/000149315216014392/ex99-1.htm


The enrollment was on the low side, 77 patients of which 56 completed the full 6 weeks. The report is still blinded as to which group is which, but most likely I think it's Group A - Low dose, Group B - High dose, Group C - Placebo (just guessing though).

They say -

'The decrease in OSA severity (change in baseline in AHI) was significantly greater for Group B than for either Group A or Group C. The greatest difference (-13.2/hr) was observed between Groups B and C. For patients with mild to moderate severity of OSA, this difference in treatment response is clinically meaningful.'

So most likely this refers to the difference between the High dose (Group B) and Placebo group (Group C). They also said that 95% of the patients in Group B expressed overall satisfaction with the treatment.

The fact that they plan to submit the results for presentation at an upcoming Sleep conference and submit a peer review manuscript is a good sign. We'll need to wait to get the full data analysis for a better picture of where we stand with the Dronabinol program, but hopefully this will generate some funding interest for RespireRx.